1. Richardson DL. The Role of the Obstetrician-Gynecologist in the Early Detection of Epithelial Ovarian Cancer in Women at Average Risk. Obstet Gynecol. 2017;130(3):e146–9.
2. Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: Epidemiology and risk factors. Int J Womens Health. 2019;11:287–99.
3. Rossing MA, Wicklund KG, Cushing-Haugen KL, Weiss NS. Predictive Value of Symptoms for Early Detection of Ovarian Cancer. JNCI J Natl Cancer Inst [Internet]. 2010 Feb 24;102(4):222–9. Available from: https://doi.org/10.1093/jnci/djp500
4. Karen J carlson. UpToDate 18. In: Barbara Goff, editor. Wolter Kluwer; 2018.
5. P. S. R, Reenu B, Prajwal S. Risk of malignancy index in ovarian tumour for predicting ovarian malignancy by using Jacob’s score. Int J Reprod Contraception, Obstet Gynecol. 2017;6(4):1318.
6. Lycke M, Kristjansdottir B, Sundfeldt K. Gynecologic Oncology A multicenter clinical trial validating the performance of HE4 , CA125 , risk of ovarian malignancy algorithm and risk of malignancy index. Gynecol Oncol [Internet]. 2018;151(1):159–65. Available from: https://doi.org/10.1016/j.ygyno.2018.08.025
7. FM H, MQ A, MKH H. Assessment of the Value of a Modified Risk of Malignancy Index (RMI) in Preoperative Discrimination Between Benign and Malignant Ovarian Masses. Gynecol Obstet. 2017 Jan 3;6(12).
8. Memirie ST, Habtemariam MK, Asefa M, Deressa BT, Abayneh G, Tsegaye B, et al. Estimates of cancer incidence in Ethiopia in 2015 using population-based registry data. J Glob Oncol. 2018;2018(4).
9. Bmg. Federal Ministry of Health. Fed Minist Heal [Internet]. 2015; Available from: http://bmg.bund.de/en.html
10. Jacobs IJ, Rivera H, Oram DH, Bast RCJ. Differential diagnosis of ovarian cancer with tumour markers CA 125, CA 15-3 and TAG 72.3. Br J Obstet Gynaecol. 1993 Dec;100(12):1120–4.
11. Hamper UM, Sheth S, Caskey CI. Color Doppler Ultrasound in the Assessment of Benign and Malignant Neoplasms of the Female Pelvis BT - Radiology of the Female Pelvic Organs. In: Lang EK, editor. Berlin, Heidelberg: Springer Berlin Heidelberg; 1998. p. 69–85. Available from: https://doi.org/10.1007/978-3-642-60260-3_4
12. Dora SK, Dandapat AB, Pande B, Hota JP. A prospective study to evaluate the risk malignancy index and its diagnostic implication in patients with suspected ovarian mass. J Ovarian Res. 2017 Aug 14;10(1).
13. Terzic M, Dotlic J, Likic I, Brndusic N, Pilic I. Risk of malignancy index validity assessment in premenopausal and postmenopausal women with adnexal tumors. TJOG [Internet]. 2013;52(2):253–7. Available from: http://dx.doi.org/10.1016/j.tjog.2013.04.017
14. Fioretti P, Gadducci A, Ferdeghini M, Prontera C, Malagnino G, Facchini V, et al. The concomitant determination of different serum tumor markers in epithelial ovarian cancer: Relevance for monitoring the response to chemotherapy and follow-up of patients. Gynecol Oncol [Internet]. 1992;44(2):155–60. Available from: http://www.sciencedirect.com/science/article/pii/009082589290031D
15. Obeidat BR, Amarin ZO, Latimer JA, Crawford RA. Risk of malignancy index in the preoperative evaluation of pelvic masses. 2004;85:255–8.
16. Bouzari Z, Yazdani S, Kelagar ZS, Abbaszadeh N. Risk of malignancy index as an evaluation of preoperative pelvic mass. Casp J Intern Med. 2011;2(4):331–5.
17. Akdeniz N, Kuyumcuoğlu U, Kale A, Erdemoğlu M, Caca F. Risk of malignancy index for adnexal masses. Eur J Gynaecol Oncol. 2009;30(2):178–80.
18. Suchitra R, Burde K, G. N, Sahithi PLS. Evaluation of the risk of malignancy index in preoperative diagnosis of ovarian masses. Int J Reprod Contraception, Obstet Gynecol. 2018;7(10):4202.
19. Grossman DC, Curry SJ, Owens DK, Barry MJ, Davidson KW, Doubeni CA, et al. Screening for ovarian cancer US preventive services task force recommendation statement. JAMA - J Am Med Assoc. 2018;319(6):588–94.
20. Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C, et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA. 2011 Jun;305(22):2295–303.
21. Aziz AB, Najmi N. Is Risk Malignancy Index a Useful Tool for Predicting Malignant Ovarian Masses in Developing Countries? Obstet Gynecol Int. 2015;2015:1–5.
22. Calster B Van, Timmerman D, Bourne T, Testa AC, Holsbeke C Van, Domali E, et al. Discrimination Between Benign and Malignant Adnexal Masses by Specialist Ultrasound Examination Versus Serum CA-125. 2007;99(22).
23. Najmi ABA and N, Aziz AB, Najmi N. Is Risk Malignancy Index a Useful Tool for Predicting Malignant Ovarian Masses in Developing Countries? Obstet Gynecol Int. 2015;2015:1–5.
24. Rujuta J, Nandita M. Risk of Malignancy Index ( RMI ) in Evaluation of Adnexal Mass. 2015;65(April):117–21.
25. Geomini P, Kruitwagen R, Bremer GL, Cnossen J, Mol BWJ. The accuracy of risk scores in predicting ovarian malignancy: a systematic review. Obstet Gynecol. 2009 Feb;113(2 Pt 1):384–94.
26. Bekele I, Yimam I. Cultural Sensitiveness in Health Care Delivery of Jimma University Specialized and Teaching. 2017;25:109–28.
27. RCOG, BSGE. Management of suspected ovarian masses in premenopausal women: Green-top Guideline No.62. R Coll Obstet Gynaecol [Internet]. 2011;(62):1–14. Available from: https://www.rcog.org.uk/globalassets/documents/guidelines/gtg_62.pdf
28. Timmerman D, Ameye L, Fischerova D, Epstein E, Melis GB, Guerriero S, et al. Simple ultrasound rules to distinguish between benign and malignant adnexal masses before surgery: prospective validation by IOTA group. BMJ [Internet]. 2010;341. Available from: https://www.bmj.com/content/341/bmj.c6839
29. Sasamoto N, Babic A, Rosner BA, Fortner RT, Vitonis AF, Yamamoto H, et al. Development and validation of circulating CA125 prediction models in postmenopausal women. J Ovarian Res. 2019;12(1):1–12.
30. Rai R, Bhutia PC, Tshomo U. Clinicopathological profile of adnexal masses presenting to a tertiary-care hospital in Bhutan. South Asian J cancer [Internet]. 2019;8(3):168–72. Available from: https://pubmed.ncbi.nlm.nih.gov/31489290
31. Moore RG, MacLaughlan S, Bast RCJ. Current state of biomarker development for clinical application in epithelial ovarian cancer. Gynecol Oncol. 2010 Feb;116(2):240–5.
32. Kurman RJ, Shih I-M. The Dualistic Model of Ovarian Carcinogenesis: Revisited, Revised, and Expanded. Am J Pathol. 2016 Apr;186(4):733–47.
33. College M, Id HEH, Mondul AM, Rozek LS, Geleta T. Descriptive Epidemiology of breast and gynecological cancers among patients attending Saint Paul ’ s Hospital Millennium. 2020;1–11. Available from: http://dx.doi.org/10.1371/journal.pone.0230625